Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
BCMA×CD3 bispecific T-cell engager
Linvoseltamab
Lynozyfic · BCMA×CD3 engager
T-cell redirection, not tubular poison — AKI rides on cytokine release, not the drug itself.
MildBCMA T-cell-redirection era (2022 onward) · approved 2025
Relapsed/refractory multiple myeloma after ≥3-4 prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody
Signature kidney injury
Prerenal / Hemodynamic AKI
No drug-specific renal toxicity signal was reported in the LINKER-MM1 registrational program; AKI is not a labeled or characteristic adverse event. Any kidney injury is expected to be indirect and infrequent, mediated chiefly by cytokine release syndrome (CRS), infection/sepsis, and (early) tumor lysis. By class analogy to CAR-T and other immune-effector therapies, AKI occurs in roughly 5-21% of T-cell-redirection recipients, is usually mild (KDIGO stage 1) and transient with recovery in ~79% within a month, and tracks with higher-grade CRS. No linvoseltamab-specific incidence is published.
Source: No linvoseltamab-specific renal incidence reported in LINKER-MM1 (Bumma 2024, PMID 38879802; Lee 2025, PMID 41387038). Class-level AKI estimates (~5-21%, mostly transient, CRS-associated) extrapolated from CAR-T/immune-effector cohorts (León-Román 2024, PMID 38500492; Rousseau 2022, PMID 36220698).
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityMild
ReversibilityReversible
Evidence0 refs
Nephron map
Vasculature / EndotheliumGlomerular & peritubular capillaries
Proximal Tubule
Distal Tubule / Collecting Duct
Tubular Lumen
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Mechanism of kidney injury
Linvoseltamab has no intrinsic tubular, glomerular, or interstitial nephrotoxic mechanism. When AKI occurs it is hemodynamic/prerenal: T-cell activation drives cytokine release syndrome (IL-6, TNF, IFN-γ) causing vasodilation, capillary leak, hypotension, and renal hypoperfusion, sometimes compounded by fever/poor intake. In heavily pretreated myeloma, baseline cast nephropathy, hypercalcemia, and infection/sepsis add to the risk. Rapid plasma-cell lysis at initiation can cause tumor lysis syndrome with uric-acid/phosphate crystal nephropathy. Electrolyte shifts (hypokalemia, hypomagnesemia, hypophosphatemia) reflect critical-illness/supportive-care effects rather than a tubular wasting signature.
Clinical presentation
Most commonly an asymptomatic, modest creatinine rise during step-up/first full-dose CRS that resolves with hydration, antipyretics, and CRS management (tocilizumab ± steroids). Severe AKI is uncommon and almost always accompanies high-grade CRS, hypotension, or sepsis. Tumor lysis, when present, manifests early with hyperuricemia, hyperphosphatemia, hyperkalemia, and oliguria. Urinalysis is typically bland (prerenal pattern); muddy-brown casts suggest superimposed ATN from prolonged hypoperfusion.
Anticancer mechanism
Linvoseltamab is a fully human IgG4-based bispecific antibody that simultaneously binds B-cell maturation antigen (BCMA/TNFRSF17) on malignant plasma cells and CD3 on T cells, forming an immunologic synapse that redirects polyclonal cytotoxic T cells to lyse myeloma cells independent of MHC restriction. Bridging triggers T-cell activation, proliferation, and release of perforin/granzyme and inflammatory cytokines, producing deep and durable myeloma responses.
Management
Manage the driver, not the drug. For CRS-associated AKI: treat CRS (tocilizumab, corticosteroids per grading), restore perfusion with isotonic fluids, and hold offending nephrotoxins. Provide TLS-directed care (aggressive hydration, rasburicase/allopurinol, electrolyte correction) when applicable. Most AKI is mild and resolves with supportive care; dose interruption is guided by CRS/overall toxicity rather than by a dedicated renal threshold. Persistent or worsening AKI warrants nephrology evaluation for superimposed ATN, cast nephropathy, or sepsis.Lesion-level management framework
Risk factors
- Higher-grade cytokine release syndrome (Grade ≥2)
- Pre-existing chronic kidney disease
- High myeloma burden / risk of tumor lysis (elevated bone-marrow plasma cells, soluble BCMA)
- Concurrent infection or sepsis
- Volume depletion / hypotension
- Light-chain cast nephropathy and hypercalcemia from underlying myeloma
- Nephrotoxic co-medications and contrast exposure
Prevention
- Mandatory step-up (split) dosing to blunt CRS severity
- Pre-medication (corticosteroid, antihistamine, antipyretic) per label during step-up
- CRS monitoring with prompt tocilizumab ± steroids; prophylactic tocilizumab reduces CRS in real-world cohorts
- Adequate hydration and avoidance of volume depletion around dosing
- TLS prophylaxis (hydration, allopurinol/rasburicase) in high-burden disease
- Treat/avoid concurrent infection; minimize nephrotoxin and contrast exposure
- Optimize myeloma-related kidney burden (hypercalcemia, light chains)
Note · Renal data are extrapolated; linvoseltamab gained FDA accelerated approval in 2025 (Lynozyfic) and the LINKER-MM1 program did not surface a discrete nephrotoxicity signal, so the prerenal/CRS-hemodynamic classification is reasoned from drug class and immune-effector-therapy literature.
Clinical depth
Renal dose adjustment
No renal dose adjustment is established. Pharmacokinetics of large IgG bispecific antibodies are not meaningfully governed by renal clearance, and the registrational program did not define renal cutoffs; patients with significant renal impairment were under-represented. Dose modification in practice is driven by CRS/ICANS and hematologic/infectious toxicity, not by creatinine.
Dialyzability & ESKD dosing
Not dialyzable. As a ~150 kDa IgG4-based bispecific antibody, linvoseltamab is eliminated by reticuloendothelial catabolism, not renal filtration, and is not removed by hemodialysis. No supplemental dosing around dialysis is indicated.
Differential diagnosis
Distinguish CRS-related hemodynamic/prerenal AKI (temporally locked to step-up dosing and fever/hypotension, bland urinalysis, rapid recovery) from: tumor lysis crystal nephropathy (early hyperuricemia/hyperphosphatemia); myeloma cast nephropathy or hypercalcemia from underlying disease; sepsis-associated ATN; and nephrotoxin/contrast injury. Unlike checkpoint inhibitors, linvoseltamab is not associated with acute interstitial nephritis, and unlike VEGF agents it does not cause hypertension/proteinuria/TMA.
Monitoring
- Serial serum creatinine/eGFR through step-up dosing and the first cycles
- CRS grading (temperature, blood pressure, oxygenation)
- Tumor lysis labs (uric acid, phosphate, potassium, calcium, LDH) at initiation in high-burden disease
- Electrolytes (K, Mg, PO4) during CRS and supportive care
- Volume status and urine output
- Infection surveillance given high infection rates in this class
Key trials & series
- LINKER-MM1 (NCT03761108) — phase 1/2 first-in-human pivotal trial; 200 mg ORR 71%, ≥CR 52%, median DOR 29.4 months
Clinical pearls
- Linvoseltamab's kidney risk is borrowed, not intrinsic — AKI rides on cytokine release syndrome, sepsis, and tumor lysis, not on direct tubular or glomerular toxicity.
- A creatinine bump during step-up dosing usually means CRS/hypoperfusion; treat the CRS and rehydrate, and renal function typically recovers.
- Not renally cleared and not dialyzable — no renal dose adjustment and no peri-dialysis dosing needed.
- Front-load TLS prophylaxis in high-burden myeloma: deep, rapid plasma-cell lysis at initiation is the main crystal-nephropathy risk window.
- No checkpoint-style AIN and no VEGF-style hypertension/proteinuria — the differential should center on hemodynamics, tumor lysis, and the patient's underlying myeloma kidney disease.
Beyond the kidney
Class-level context for the major non-renal toxicities of bcma×cd3 bispecific t-cell engagers.
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
- Cytokine release syndrome
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- ICANS / neurotoxicity
Hematologic
Cytopenias, thrombosis, TMA
- Cytopenias, hypogammaglobulinemia
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkLinvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.Bumma N et al. · J Clin Oncol 2024 · PMID 38879802Pivotal LINKER-MM1 phase 1/2 registrational trial: efficacy and full safety profile (CRS 46%, infections, neutropenia); no discrete renal toxicity signal — basis for the prerenal/CRS-driven classification.PMIDLinvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.Lee HC et al. · Clin Lymphoma Myeloma Leuk 2025 · PMID 41387038Updated LINKER-MM1 analysis (median 21.3-mo follow-up) confirming durable responses, CRS mostly during step-up dosing, and no new safety signals — supports low/indirect renal risk.PMIDAn evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma.Avigan ZM et al. · Expert Opin Biol Ther 2025 · PMID 39923122Drug evaluation/review contextualizing linvoseltamab's CRS kinetics and safety among approved BCMA bispecifics — supports class-level toxicity framing.PMIDTocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies.Kowalski A et al. · Blood Adv 2025 · PMID 40590849Real-world cohort including linvoseltamab showing prophylactic tocilizumab markedly lowers CRS — directly informs prevention of the CRS-mediated hemodynamic AKI pathway.PMIDTransient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies.León-Román J et al. · Clin Kidney J 2024 · PMID 38500492Onconephrology cohort: AKI in ~21% of immune-effector recipients, independently associated with higher-grade CRS/ICANS and reversible in ~79% within a month — the class analogy for linvoseltamab's prerenal pattern.PMIDAcute kidney injury after CAR-T cell infusion.Rousseau A, Zafrani L. · Bull Cancer 2022 · PMID 36220698Review of AKI mechanisms after T-cell-redirection therapy (CRS hypoperfusion, cytokine injury, tumor lysis, sepsis) — mechanistic basis for the prerenal/crystal/electrolyte injury set.
Related agents
Other agents sharing the same signature kidney injury.